WeLeader Biomedical (7713) Monthly Revenue

Market: TPEx (OTC) · Industry: Biotech & Medical · 威力德生醫

WeLeader Biomedical (7713) reported revenue of NT$112.6 million for Oct 2026, +15.3% year on year and -3.4% from the previous month. Revenue for Jan–Oct 2026 was NT$1.08 billion (+18.8% year on year).

Year-on-year revenue growth: 21 months in a row. →

In Oct 2026, it ranked No. 68 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$80.1 million24/10Nov 2024 NT$88 millionDec 2024 NT$79.8 millionJan 2025 NT$80.7 millionFeb 2025 NT$74.9 million25/02Mar 2025 NT$89.5 millionApr 2025 NT$82.8 millionMay 2025 NT$92.3 millionJun 2025 NT$97.9 million25/06Jul 2025 NT$94.9 millionAug 2025 NT$101.2 millionSep 2025 NT$99.8 millionOct 2025 NT$97.7 million25/10Nov 2025 NT$100.9 millionDec 2025 NT$96.6 millionJan 2026 NT$98.3 millionFeb 2026 NT$78.3 million26/02Mar 2026 NT$102.3 millionApr 2026 NT$115 millionMay 2026 NT$111.3 millionJun 2026 NT$112.9 million26/06Jul 2026 NT$120 millionAug 2026 NT$116.2 millionSep 2026 NT$116.6 millionOct 2026 NT$112.6 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$112.6 million+15.3%-3.4%
Sep 2026NT$116.6 million+16.8%+0.3%
Aug 2026NT$116.2 million+14.8%-3.2%
Jul 2026NT$120 million+26.4%+6.3%
Jun 2026NT$112.9 million+15.2%+1.4%
May 2026NT$111.3 million+20.6%-3.2%
Apr 2026NT$115 million+38.8%+12.3%
Mar 2026NT$102.3 million+14.3%+30.6%
Feb 2026NT$78.3 million+4.6%-20.3%
Jan 2026NT$98.3 million+21.7%+1.8%
Dec 2025NT$96.6 million+21.0%-4.3%
Nov 2025NT$100.9 million+14.7%+3.3%
Oct 2025NT$97.7 million+22.0%-2.1%
Sep 2025NT$99.8 million+25.8%-1.4%
Aug 2025NT$101.2 million+10.2%+6.6%
Jul 2025NT$94.9 million+12.5%-3.1%
Jun 2025NT$97.9 million+0.1%+6.1%
May 2025NT$92.3 million+14.9%+11.5%
Apr 2025NT$82.8 million+11.3%-7.5%
Mar 2025NT$89.5 million+6.3%+19.6%
Feb 2025NT$74.9 million+10.7%-7.3%
Jan 2025NT$80.7 million-2.9%+1.1%
Dec 2024NT$79.8 million+1.5%-9.2%
Nov 2024NT$88 million+15.2%+9.8%
Oct 2024NT$80.1 million+5.9%+1.0%

Jan–Oct 2026 cumulative: NT$1.08 billion (+18.8% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: WeLeader Biomedical vs PEC / WeLeader Biomedical vs Lotus Pharm / WeLeader Biomedical vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16